NASDAQ:XGN - Nasdaq - US30068X1037 - Common Stock - Currency: USD
Taking everything into account, XGN scores 2 out of 10 in our fundamental rating. XGN was compared to 566 industry peers in the Biotechnology industry. Both the profitability and financial health of XGN have multiple concerns. XGN is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -33.82% | ||
ROE | -158.44% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 59.51% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.09 | ||
Debt/FCF | N/A | ||
Altman-Z | -6.49 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.7 | ||
Quick Ratio | 2.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:XGN (5/2/2025, 8:00:02 PM)
6.02
-0.12 (-1.95%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 1.94 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 11.3 | ||
P/tB | 11.3 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -33.82% | ||
ROE | -158.44% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 59.51% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.09 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 29.87% | ||
Cap/Sales | 0.93% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.7 | ||
Quick Ratio | 2.7 | ||
Altman-Z | -6.49 |